Aosaikang's leuterinib achieves breakthrough in lung cancer treatment

Beijing Aosaikang Pharmaceutical (SZSE:002755) announced that its innovative drug, leuterinib (Aoyixing®), has demonstrated significant efficacy in a Phase III clinical study, the results of which were published in *The Lancet Respiratory Medicine*. Leuterinib, a third-generation EGFR TKI, is designed for first and second-line treatment of adults with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).